• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The Importance of Panitumumab in Radiotherapy Involving Head and Neck Region.帕尼单抗在头颈部放疗中的重要性。
J Maxillofac Oral Surg. 2019 Mar;18(1):159-160. doi: 10.1007/s12663-018-1138-8. Epub 2018 Jul 27.
2
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.帕尼单抗联合放疗对比放化疗用于治疗不可切除的局部晚期头颈部鳞状细胞癌患者（CONCERT-2）：一项随机、对照、开放标签的 2 期临床试验。
Lancet Oncol. 2015 Feb;16(2):221-32. doi: 10.1016/S1470-2045(14)71200-8. Epub 2015 Jan 15.
3
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.在未切除的局部晚期头颈部鳞状细胞癌患者中进行放化疗联合或不联合 panitumumab 的效果比较（CONCERT-1）：一项随机、对照、开放性二期临床试验。
Lancet Oncol. 2015 Feb;16(2):208-20. doi: 10.1016/S1470-2045(14)71198-2. Epub 2015 Jan 15.
4
Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.高危可切除头颈癌患者术后放疗联合顺铂和帕尼单抗的II期试验
Ann Oncol. 2016 Dec;27(12):2257-2262. doi: 10.1093/annonc/mdw428. Epub 2016 Oct 11.
5
PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.PRISM：帕尼单抗单药作为复发或转移性头颈部鳞状细胞癌患者二线治疗的2期试验。
Head Neck. 2016 Apr;38 Suppl 1:E1756-61. doi: 10.1002/hed.24311. Epub 2015 Dec 17.
6
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.紫杉醇联合帕尼单抗、卡铂和调强放疗治疗局部晚期头颈部鳞状细胞癌的 I 期剂量探索研究。
Ann Oncol. 2010 Feb;21(2):342-347. doi: 10.1093/annonc/mdp477. Epub 2009 Nov 5.
7
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.帕尼单抗与紫杉醇联合用于复发或转移性头颈癌一线治疗的II期研究。TTCC-2009-03/VECTITAX研究。
Oral Oncol. 2016 Nov;62:54-59. doi: 10.1016/j.oraloncology.2016.09.009. Epub 2016 Oct 8.
8
PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.伙伴研究：一项开放标签、随机、2期研究，评估多西他赛/顺铂化疗联合或不联合帕尼单抗作为复发性或转移性头颈部鳞状细胞癌一线治疗的疗效。
Oral Oncol. 2016 Oct;61:31-40. doi: 10.1016/j.oraloncology.2016.07.005. Epub 2016 Aug 20.
9
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.顺铂和氟尿嘧啶联合或不联合帕尼单抗治疗复发性或转移性头颈部鳞状细胞癌（SPECTRUM）：一项开放标签的 3 期随机试验。
Lancet Oncol. 2013 Jul;14(8):697-710. doi: 10.1016/S1470-2045(13)70181-5. Epub 2013 Jun 6.
10
Molecularly targeted therapies in head and neck cancers.头颈部癌症的分子靶向治疗
Otolaryngol Pol. 2012 Sep-Oct;66(5):307-12. doi: 10.1016/j.otpol.2012.06.021. Epub 2012 Jul 2.

本文引用的文献

1
Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.用于治疗结直肠肿瘤的免疫疗法：聚焦于已获批及正在进行临床试验的单克隆抗体。
Drug Des Devel Ther. 2017 Jan 11;11:177-184. doi: 10.2147/DDDT.S119036. eCollection 2017.
2
Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.顺铂同步标准放疗与帕尼单抗同步加速放疗治疗局部晚期头颈部鳞状细胞癌的疗效：一项随机临床试验
JAMA Oncol. 2017 Feb 1;3(2):220-226. doi: 10.1001/jamaoncol.2016.4510.
3
Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.高危可切除头颈癌患者术后放疗联合顺铂和帕尼单抗的II期试验
Ann Oncol. 2016 Dec;27(12):2257-2262. doi: 10.1093/annonc/mdw428. Epub 2016 Oct 11.
4
Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.帕尼单抗作为野生型KRAS转移性结直肠癌患者一线治疗的概况。
Onco Targets Ther. 2015 Dec 30;9:75-86. doi: 10.2147/OTT.S68558. eCollection 2016.
5
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.在未切除的局部晚期头颈部鳞状细胞癌患者中进行放化疗联合或不联合 panitumumab 的效果比较（CONCERT-1）：一项随机、对照、开放性二期临床试验。
Lancet Oncol. 2015 Feb;16(2):208-20. doi: 10.1016/S1470-2045(14)71198-2. Epub 2015 Jan 15.
6
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.帕尼单抗联合放疗对比放化疗用于治疗不可切除的局部晚期头颈部鳞状细胞癌患者（CONCERT-2）：一项随机、对照、开放标签的 2 期临床试验。
Lancet Oncol. 2015 Feb;16(2):221-32. doi: 10.1016/S1470-2045(14)71200-8. Epub 2015 Jan 15.
7
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.人乳头瘤病毒相关头颈部癌患者中同步放化疗联合表皮生长因子受体抑制剂与放化疗联合顺铂的疗效差异。
BMC Cancer. 2013 Jan 18;13:26. doi: 10.1186/1471-2407-13-26.

The Importance of Panitumumab in Radiotherapy Involving Head and Neck Region.

作者信息

Cihan Yasemin Benderli

机构信息

Department of Radiation Oncology, Kayseri Education and Research Hospital, 38010 Kayseri, Turkey.

出版信息

J Maxillofac Oral Surg. 2019 Mar;18(1):159-160. doi: 10.1007/s12663-018-1138-8. Epub 2018 Jul 27.

DOI:10.1007/s12663-018-1138-8
PMID:30728710
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6328827/
Abstract
摘要